Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
Wei Zhen YehPutu Ayu WidyastutiAnneke Van Der WaltJim StankovichEva HavrdovaDana HorakovaKarolina VodehnalovaSerkan OzakbasSara EichauPierre DuquetteTomas KalincikFrancesco PattiCavit BozMurat TerziBassem I YamoutJeannette Lechner-ScottPatrizia SolaOlga G SkibinaMichael Harry BarnettMarco OnofrjMaria José SáPamela Ann McCombePierre GrammondRadek AmpapaFrancois Grand'MaisonRoberto BergamaschiDaniele L A SpitaleriVincent van PeschElisabetta CartechiniSuzanne HodgkinsonAysun SoysalAlbert SaizMelissa GresleTomas UherDavide MaimoneRecai TurkogluRaymond Mm HuppertsMaria Pia AmatoFranco GranellaCelia Oreja-GuevaraAyse AltintasRichard A MacdonellTamara Castillo-TrivinoHelmut ButzkuevenRaed AlroughaniVilija G Jokubaitisnull nullPublished in: Neurology (2021)
Intrapartum and postpartum relapse probabilities increased among women with MS after natalizumab or fingolimod cessation. In women considered to be at high relapse risk, use of natalizumab before pregnancy and continued up to 34 weeks gestation, with early re-initiation after delivery is an effective option to minimize relapse risks. Strategies of DMT use have to be balanced against potential fetal/neonatal complications.